Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- Changhai Hospital
- Enrollment
- 600
- Locations
- 1
- Primary Endpoint
- Gastrointestinal microbiota
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The investigators plan to collect throat swabs, saliva, feces and serum samples from pancreatic cancer patients, chronic pancreatitis patients and healthy people and clarify the characteristics of oral flora and serum metabolome of pancreatic cancer patients.
Investigators
Xiangyu Kong
Principle Investigator
Changhai Hospital
Eligibility Criteria
Inclusion Criteria
- •1.Pathologic diagnosis of pancreatic ductal adenocarcinoma；Diagnosis of CP defined as having obvious morphological features of CP (i.e., the presence of pancreatic calcifications on CT scan and/or magnetic resonance cholangiopancreatography)；Other benign disease populations without pancreatic lesions.
Exclusion Criteria
- •Pregnant women.
- •Patients with coagulation disorders who are unable to undergo blood tests.
- •Have a history of using antibiotics or probiotics within the past 3 months.
Outcomes
Primary Outcomes
Gastrointestinal microbiota
Time Frame: Baseline
Perform 16S RNA sequence and shotgun metagenomic analysis of fecal, throat swabs and salivary samples collected from pancreatic cancer patients, chronic pancreatitis patients and healthy people.
Overall Survival
Time Frame: up to 2 years
The length of time (in days) from study enrollment that participants remain alive.
Predictive model
Time Frame: up to 2 years
Combined with preoperative imaging and pathological information, a predictive model of pancreatic cancer would be established based on the metabolic and microbiota difference. Verify the stability and accuracy of our model in larger cohorts and promote clinical translation.
serum metabolites
Time Frame: Baseline
Perform Untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyse serum samples collected from pancreatic cancer patients, chronic pancreatitis patients and healthy people.